Journal
SEMINARS IN ONCOLOGY
Volume 41, Issue 5, Pages 661-666Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.seminoncol.2014.08.005
Keywords
-
Categories
Funding
- National Institutes of Health-NCI [R01 CA142636]
- Department of Defense and Technology/Therapeutic Development Award [W81XWH-10-10425]
- SCOR grant from the Leukemia and Lymphoma Society
- SPORE in Lymphoma [P50CA126752]
Ask authors/readers for more resources
Monoclonal antibodies (mAbs) and their directly derived cell-based application known as chimeric antigen receptors (CARs) ensue from the need to develop novel therapeutic strategies that retain high anti-tumor activity, but carry reduced toxicity compared to conventional chemo- and radiotherapies. In this concise review article, we will summarize the application of antibodies designed to target antigens expressed by tumor cells, and the transition from these antibodies to the generation of CARs. (C) 2014 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available